[{"data":1,"prerenderedAt":256},["ShallowReactive",2],{"drug-methylphenidate":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":21,"regimens":53,"contraindications":115,"warnings":134,"renal":142,"monitoring":143,"interactions":150,"review":151,"examples":154,"atc":168,"iran":170,"links":198,"populations":218,"usApproval":251},"methylphenidate",1,{"fa":7,"en":8},"متیل‌فنیدیت","Methylphenidate","nervous-system",{"fa":11,"en":12},"محرک CNS","CNS stimulant",[14],{"name":15,"market":16},"Ritalin","US",[18,19,20],"ritalin","ریتالین","متیل فنیدیت",[22,36,45],{"id":23,"form":24,"route":25,"label":26,"concentration":27,"markets":31,"refs":32},"tab-5","tablet","oral","5 mg tablet",{"amount":28,"unit":29,"perUnit":24,"scored":30},5,"mg",false,[16],[33],{"source":34,"section":35},"fda-ritalin","3",{"id":37,"form":24,"route":25,"label":38,"concentration":39,"markets":42,"refs":43},"tab-10","10 mg tablet (partial bisection)",{"amount":40,"unit":29,"perUnit":24,"scored":41},10,true,[16],[44],{"source":34,"section":35},{"id":46,"form":24,"route":25,"label":47,"concentration":48,"markets":50,"refs":51},"tab-20","20 mg tablet (partial bisection)",{"amount":49,"unit":29,"perUnit":24,"scored":41},20,[16],[52],{"source":34,"section":35},[54,93],{"id":55,"disease":56,"label":57,"population":60,"type":66,"unit":29,"dose":67,"refs":72,"notes":77},"child","adhd",{"fa":58,"en":59},"ADHD — ۶ سال به بالا: شروع ۵ mg دو بار در روز","ADHD — ≥6 years: start 5 mg twice daily",{"minAge":61,"maxAge":64},{"value":62,"unit":63},6,"year",{"value":65,"unit":63},18,"titration",{"dividedDoses":68,"titration":69},2,{"start":40,"increment":28,"incrementEveryDays":70,"max":71},7,60,[73,75],{"source":34,"section":74},"2.2",{"source":34,"section":76},"8.4",[78,86],{"text":79,"refs":82},{"fa":80,"en":81},"قبل از صبحانه و ناهار؛ افزایش هفتگی ۵ تا ۱۰ mg؛ بیش از ۶۰ mg\u002Fday توصیه نمی‌شود. اگر پس از یک ماه بهبود نبود قطع شود.","Before breakfast and lunch; increase 5–10 mg weekly; above 60 mg\u002Fday not recommended. Discontinue if no improvement after one month.",[83,84],{"source":34,"section":74},{"source":34,"section":85},"2.3",{"text":87,"refs":90},{"fa":88,"en":89},"پیش از شروع: بیماری قلبی، سابقه خانوادگی مرگ ناگهانی و تیک\u002Fتورت بررسی شود.","Before starting: screen for cardiac disease, family history of sudden death, tics\u002FTourette's.",[91],{"source":34,"section":92},"2.1",{"id":94,"disease":56,"label":95,"population":98,"type":100,"unit":29,"dose":101,"refs":103,"limits":105,"notes":108},"adult",{"fa":96,"en":97},"بزرگسال — معمولاً ۲۰ تا ۳۰ mg روزانه در ۲ تا ۳ نوبت","Adults — usually 20–30 mg daily in 2–3 doses",{"minAge":99},{"value":65,"unit":63},"fixed",{"perDose":40,"perDoseMax":102,"dosesPerDay":68},15,[104],{"source":34,"section":74},{"maxPerDay":71,"refs":106},[107],{"source":34,"section":74},[109],{"text":110,"refs":113},{"fa":111,"en":112},"۳۰ تا ۴۵ دقیقه قبل از غذا؛ آخرین دوز قبل از ساعت ۶ عصر در صورت بی‌خوابی. حداکثر ۶۰ mg\u002Fday.","30–45 min before meals; last dose before 6 p.m. if insomnia. Max 60 mg\u002Fday.",[114],{"source":34,"section":74},[116,125],{"id":117,"severity":118,"text":119,"refs":122},"maoi","block",{"fa":120,"en":121},"مصرف MAOI یا تا ۱۴ روز پس از قطع (بحران فشار خون)؛ حساسیت.","MAOI within 14 days (hypertensive crisis); hypersensitivity.",[123],{"source":34,"section":124},"4",{"id":126,"severity":118,"rule":127,"text":129,"refs":132},"under-6",{"maxAge":128},{"value":62,"unit":63},{"fa":130,"en":131},"بی‌خطری زیر ۶ سال ثابت نشده است.","Not established under 6 years.",[133],{"source":34,"section":76},[135],{"text":136,"refs":139},{"fa":137,"en":138},"هشدار جعبه‌ای: احتمال بالای سوءمصرف، مصرف نادرست و اعتیاد؛ خطر اوردوز و مرگ.","Boxed warning: high potential for abuse, misuse and addiction; risk of overdose and death.",[140],{"source":34,"section":141},"WARNING: ABUSE, MISUSE, AND ADDICTION",[],[144],{"text":145,"refs":148},{"fa":146,"en":147},"رشد (قد و وزن) کودکان در طول درمان پایش شود.","Monitor growth (height and weight) during treatment.",[149],{"source":34,"section":76},[],{"status":152,"reviewer":153,"date":153},"unverified",null,[155,160,164],{"regimen":55,"formulation":23,"input":156,"expect":159},{"ageYears":157,"weightKg":158},8,25,{"perDose":28,"tabletsPerDoseRounded":5},{"regimen":94,"formulation":37,"input":161,"expect":163},{"ageYears":158,"weightKg":162},70,{"perDose":40,"upperPerDose":102},{"regimen":55,"formulation":23,"input":165,"expect":166},{"ageYears":28,"weightKg":65},{"status":167},"blocked",[169],"N06BA04",{"status":171,"forms":172,"refs":193},"registered",[173,177,181,185,189],{"code":174,"en":175,"fa":176},"01328","METHYLPHENIDATE HCL 10MG TAB","قرص متیل‌فنیدات هیدروکلراید ۱۰ میلی‌گرم",{"code":178,"en":179,"fa":180},"07991","METHYLPHENIDATE HCL 20MG SR TAB","قرص آهسته‌رهش متیل‌فنیدات هیدروکلراید ۲۰ میلی‌گرم",{"code":182,"en":183,"fa":184},"50684","METHYLPHENIDATE HCL TABLET, EXTENDED RELEASE ORAL 18 mg","قرص آهسته‌رهش متیل‌فنیدات هیدروکلراید ۱۸ میلی‌گرم",{"code":186,"en":187,"fa":188},"50685","METHYLPHENIDATE HCL TABLET, EXTENDED RELEASE ORAL 36 mg","قرص آهسته‌رهش متیل‌فنیدات هیدروکلراید ۳۶ میلی‌گرم",{"code":190,"en":191,"fa":192},"50686","METHYLPHENIDATE HCL TABLET, EXTENDED RELEASE ORAL 54 mg","قرص آهسته‌رهش متیل‌فنیدات هیدروکلراید ۵۴ میلی‌گرم",[194],{"source":195,"section":196,"url":197},"darooyab-generic","G-3392\u002FMethylphenidate","https:\u002F\u002Fwww.darooyab.ir\u002FG-3392\u002FMethylphenidate",[199,203,207,210,213,216],{"kind":200,"url":201,"label":202},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=010187","NDA010187",{"kind":204,"url":205,"label":206},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=d6fb2750-cdab-4749-ba0d-7534840a5892","FDA Ritalin",{"kind":208,"url":209,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa682188.html",{"kind":208,"url":211,"label":212},"https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa606014.html","Methylphenidate Transdermal Patch",{"kind":214,"url":215,"label":169},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N06BA04",{"kind":217,"url":197,"label":8},"darooyab",{"pregnancy":219,"lactation":228,"pediatric":236,"geriatric":243},{"level":220,"text":221,"quote":224,"refs":225},"caution",{"fa":222,"en":223},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Published studies and postmarketing reports on methylphenidate use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.",[226],{"source":34,"section":227},"8.1",{"level":220,"text":229,"quote":232,"refs":233},{"fa":230,"en":231},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Limited published literature, based on milk sampling from seven mothers, reports that methylphenidate is present in human milk, which resulted in infant doses of 0.16% to 0.7% of the maternal weight-adjusted dosage and a milk\u002Fplasma ratio ranging between 1.1 and 2.7.",[234],{"source":34,"section":235},"8.2",{"level":220,"text":237,"quote":240,"refs":241},{"fa":238,"en":239},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of Ritalin for the treatment of ADHD have been established in pediatric patients aged 6 to 17 years.",[242],{"source":34,"section":76},{"level":220,"text":244,"quote":247,"refs":248},{"fa":245,"en":246},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Ritalin has not been studied in the geriatric population.",[249],{"source":34,"section":250},"8.5",{"kind":252,"refs":253,"id":202},"NDA",[254],{"source":34,"section":255},"SPL approval \u002F marketing category",1792191877657]